Clinical trial
PS-341 in Treating Women With Metastatic Breast Cancer
NCT00028639 · Northwestern University, Other · Completed
Key facts
| NCT number | NCT00028639 |
|---|---|
| Title | PS-341 in Treating Women With Metastatic Breast Cancer |
| Official title | A Phase II Study of the Proteasome Inhibitor PS-341 (NSC 681 239) in Patients With Metastatic Breast Cancer |
| Lead sponsor | Northwestern University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | bortezomib |
| Start date | Aug 1, 2001 |
| Primary completion | Nov 1, 2003 |
| Completion | Nov 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 29, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: